Nov 4, 7:04 AM ET
Charles River Laboratories International reported third-quarter 2026 revenue of $982.7 million and increased its full-year guidance for revenue and non-GAAP earnings per share. The results were driven by a 4.7% increase in organic revenue and a lower tax rate, alongside a significant benefit from the reversal of acquired tax reserves.
- Third-quarter revenue reached $982.7 million, with organic revenue growing 4.7% year-over-year.
- GAAP earnings per share were $6.86 and non-GAAP earnings per share were $3.09 for the quarter ended September 26, 2026.
- Full-year 2026 GAAP EPS estimate was updated to $8.15 to $8.35 and non-GAAP EPS estimate to $11.35 to $11.55.
Read the filing on SEC.gov ↗
Aug 5, 7:15 AM ET
Charles River reported second-quarter 2026 revenue of $1.00 billion, down 2.7% from a year earlier, and non-GAAP earnings per share of $3.02, down 3.2%. A $63.7 million loss on the CDMO and Cell Solutions divestiture produced a GAAP net loss of $(1.5) million, or $(0.03) per diluted share. The company raised its 2026 non-GAAP EPS guidance but lowered its GAAP EPS guidance.
- Q2 revenue $1.00 billion, down 2.7% from $1.03 billion; organic revenue up 0.1%
- GAAP net loss $(1.5) million, or $(0.03) per diluted share, vs. net income of $52.3 million, or $1.06, a year earlier
- Non-GAAP EPS $3.02, down 3.2% from $3.12; non-GAAP operating margin 20.5% vs. 22.1%
- 2026 non-GAAP EPS guidance raised to $11.15–$11.45 from $10.80–$11.30; GAAP EPS guidance cut to $3.05–$3.35 from $5.35–$5.85
Read the filing on SEC.gov ↗
May 11, 5:01 PM ET
At its May 5, 2026 annual meeting, Charles River Laboratories shareholders elected all 12 director nominees, approved a new 2026 Long-Term Incentive Plan, approved executive pay on an advisory basis, and ratified PricewaterhouseCoopers LLP as auditor for fiscal 2026. The votes are routine annual-meeting matters with no change in financial results or guidance reported in this filing.
- All 12 directors were elected to serve until the 2027 annual meeting; each received more votes for than against.
- The 2026 Long-Term Incentive Plan was approved with 41,523,179 votes for and 2,561,994 against.
- Advisory say-on-pay was approved with 41,356,139 votes for and 2,716,251 against.
- PricewaterhouseCoopers LLP was ratified as independent auditor for fiscal 2026 with 43,646,371 votes for.
Read the filing on SEC.gov ↗
May 7, 7:14 AM ET
Charles River reported first-quarter 2026 revenue of $995.8 million, up 1.2% from a year earlier but down 1.5% on an organic basis. The GAAP net loss was $14.8 million, or $0.30 per diluted share, mainly due to a $118.0 million loss on assets held for sale tied to the CDMO and Cell Solutions divestiture, which closed May 6, 2026. Non-GAAP EPS was $2.06, down 12.0%, and the company reaffirmed its 2026 organic revenue and non-GAAP EPS guidance while lowering its reported revenue outlook by about 50 basis points.
- Revenue was $995.8 million, up 1.2%; organic revenue declined 1.5%.
- GAAP net loss of $14.8 million, or $0.30 per diluted share, versus net income of $25.5 million, or $0.50, in Q1 2025.
- Non-GAAP diluted EPS was $2.06, down 12.0% from $2.34 a year earlier.
- 2026 non-GAAP EPS guidance of $10.80 to $11.30 was reaffirmed; reported revenue outlook was cut by about 50 basis points on foreign exchange assumptions.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.